Fulminant Clostridium difficile colitis in a post-liver transplant patient.
Lee
Maximilian
M
Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University Medical Center, 300 Pasteur Dr., Always Bldg. M211, Stanford, CA 94305-5187, USA. maxlee@stanford.edu
Shelton
Andrew A
AA
Concepcion
Waldo L
WL
Bonham
Clark A
CA
Daugherty
Tami J
TJ
D000328:Adult; D000900:Anti-Bacterial Agents / Q000009:adverse effects; D001426:Bacterial Proteins / Q000235:genetics; D001427:Bacterial Toxins / Q000235:genetics; D016360:Clostridioides difficile / Q000235:genetics / Q000302:isolation & purification*; D003082:Colectomy; D003106:Colon / Q000000981:diagnostic imaging / Q000382:microbiology* / Q000473:pathology / Q000601:surgery; D003161:Compartment Syndromes / Q000382:microbiology; D004761:Enterocolitis, Pseudomembranous / Q000000981:diagnostic imaging / Q000382:microbiology* / Q000473:pathology / Q000601:surgery; D005243:Feces / Q000382:microbiology; D005260:Female; D006801:Humans; D007081:Ileostomy; D007166:Immunosuppressive Agents / Q000009:adverse effects; D016031:Liver Transplantation / Q000009:adverse effects*; D009102:Multiple Organ Failure / Q000382:microbiology; D016133:Polymerase Chain Reaction; D011860:Radiography, Abdominal; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D001426:Bacterial Proteins; D001427:Bacterial Toxins; D007166:Immunosuppressive Agents; C031815:toxB protein, Clostridium difficile